Allogene CAR-Ts’ Durability Remains A Question, But Strong Data So Far

Pivotal Trial Likely To Include Consolidation Dosing

 
• By Alaric DeArment
  
Digital illustration of Cancer cell in colour background
Allogene announced data for its off-the-shelf CAR-Ts in non-Hodgkin's lymphoma • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASCO

More from Conferences